ArticleCancers2021

Mutations Associated with No Durable Clinical Benefit to Immune Checkpoint Blockade in Non-S-Cell Lung Cancer.

Guangsheng Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.